Decartes-08
Phase 3Biologic
Decartes-08 is one of 48 biologic programs targeting Myasthenia Gravis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Myasthenia Gravis
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Ultomiris
AstraZenecaPhase 3
Vyvgart
ArgenxPhase 3
Zilbrysq
UCBPhase 3
Cellcept
RochePhase 3
Soliris
AstraZenecaPhase 3
Fabhalta
Johnson & JohnsonPhase 3
Arava
SanofiPhase 3
Rhapsido
NovartisPhase 3
ENSPRYNG
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Decartes-08. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- CCartesian Therapeutics